| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2166978 | Cellular Immunology | 2014 | 8 Pages |
•Levels of cfDNA are significantly higher in SLE patients than in healthy controls.•No differences existed between the DNA integrity of SLE patients and controls.•Changes in disease state are reflected by fluctuations of cfDNA concentrations.•cfDNA is a possible global clinical marker for disease activity in SLE patients.
High levels of cell free DNA (cfDNA) in human blood plasma have been described in patients with autoimmune diseases. The aim of this study was to determine the levels of cfDNA in systemic lupus erythematosus (SLE) patients and to assess fluctuations of cfDNA concentrations compared to the course of disease progression under standard treatment. Therefore, nuclear cfDNA concentrations in plasma were measured in 59 SLE patients and 59 healthy controls. Follow-up blood plasma was collected from 27 of the 59 SLE patients. Patients were characterised by clinical parameters (antinuclear antibodies (ANA), anti-dsDNA-antibodies, C3, C4, and CRP), SLE disease activity index (SLEDAI) and medical therapy. Our results showed that cfDNA concentrations were significantly higher in SLE patients compared to healthy individuals. Levels of cfDNA assessed in serial samples correlated significantly with the medical evaluation of disease activity in SLE patients. Our results could implicate cfDNA as a global marker for disease activity.
